Answers are grounded in this paper and cite their sources.
Objectives Omadacycline was tested against 7000 bacterial isolates collected prospectively from medical centres in the USA during 2019. Methods Antimicrobial susceptibility testing was performed according to Clinical and Laboratory Standards Institute (CLSI) guidelines. Results Omadacycline was active against: Staphylococcus aureus (MIC 50/90 , 0.12/0.25 mg/L; 98.3% susceptible), including methicillin-resistant S. aureus (MRSA); Enterococcus faecalis (MIC 50/90 , 0.06/0.25 mg/L; 100.0% susceptible), including vancomycin-resistant enterococci (VRE); Streptococcus pneumoniae (MIC 50/90 , 0.06/0.06 mg/L; 99.8% susceptible); viridans group streptococci, including Streptococcus anginosus group (MIC 50/90 , 0.03/0.06 mg/L; 100.0% susceptible); β-haemolytic streptococci, including Streptococcus pyogenes (MIC 50/90 , 0.06/0.12 mg/L; 99.2% susceptible); Enterobacterales (MIC 50/90 , 1/8 mg/L; 86.9% inhibited at ≤4 mg/L), including Escherichia coli (MIC 50/90 , 0.5/2 mg/L; 99.6% inhibited at ≤4 mg/L); Enterobacter cloacae (MIC 50/90 , 2/4 mg/L; 98.5% susceptible); Klebsiella pneumoniae (MIC 50/90 , 1/4 mg/L; 93.2% susceptible); Acinetobacter baumannii (MIC 50/90 , 0.5/4 mg/L; 90.8% inhibited at ≤4 mg/L); Haemophilus influenzae (MIC 50/90 , 0.5/1 mg/L; 100.0% susceptible); and Moraxella catarrhalis (MIC 50/90 , ≤0.12/0.25 mg/L). Conclusion The 2019 in vitro activity of omadacycline against key Gram-positive and Gram-negative pathogens has not changed compared with the prior 3 years of surveillance in the SENTRY Antimicrobial Surveillance Program. Omadacycline merits further study in serious infections where resistant pathogens may be encountered.
No takes yet. Share an insight, caveat, or question.
Pfaller et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: